Eric Nuermberger, MD

Faculty

Titles:

Associate Professor, Medicine

Email:

Eric Nuermberger

SciVal:

SciVal Link

The primary research focus in my laboratory is translational research related to TB drug development. Using established animal and in vitro models of active and latent TB infection and relying on pharmacodynamic principles, our major goal is to identify and optimize new drugs and drug combinations to shorten and/or simplify TB treatment and restrict the emergence of drug resistance. Over the past 15 years, our work has informed the development of a number of new and repurposed drugs, including moxifloxacin, rifapentine, bedaquiline, PA-824, and the oxazolidinones sutezolid and linezolid, as well as novel combinations containing these drugs. We continue to refine existing models and develop new models for pre-clinical drug efficacy studies, including murine models of cavitary TB and a flow-controlled in vitro system for studying the pharmacodynamics of new drugs and combinations.    

A second research interest is applying similar approaches to improve the treatment of Buruli ulcer, an emerging yet neglected tropical disease characterized by enlarging and ultimately disabling skin ulcers caused by infection with Mycobacterium ulcerans and production of its unique cytotoxin mycolactone. Only in the last decade has chemotherapy replaced surgery as the preferred therapeutic option, especially for early lesions. However, early lesions are difficult to detect with available diagnostics and the current regimen of streptomycin and rifampin for 8 weeks has many drawbacks. We aim to translate advances in the TB drug development space and novel ideas for detection of mycolactone in biological samples to improve therapeutics and point-of-care diagnostics.

Categories

Events

«

October 2017

»
S
M
T
W
T
F
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
·
·
·
·

Projects

APT: Assessing PA-824 for Tuberculosis

A Phase 2 clinical trial of PA-824, an investigational nitroimidazole, as part of multidrug therapy for pulmonary TB; in...

Read More

Assessing the social value of novel regimens...

We are collaborating with investigators from the Berman Bioethics Institute to develop novel techniques for economic evaluation...

Read More

Understanding the impact of combined TB and...

We are developing models to understand the overlap of TB and HIV in three epidemiologically distinct settings (Canada, India,...

Read More

TB Modeling and Analysis Consortium

The TB MAC brings TB modelers together from a wide range of institutions to answer questions of global policy relevance.  I...

Read More

TBM-KIDS (Malawi)

A phase 2 clinical trial of optimized treatment for pediatric tuberculous meningitis in India and Malawi

Read More